可调节经闭孔男性系统(ATOMS)的长期结局:一项欧洲多中心研究结果
该欧洲多中心研究纳入2009年6月至2016年3月接受ATOMS装置治疗的287例男性压力性尿失禁患者,中位随访31个月、中位调整3次后,总体成功率为90%(258例),干爽率为64%(184例),每日尿垫试验和尿垫使用量均显著下降,生活质量显著改善,装置安全,最新一代硅胶覆盖阴囊端口优于前代。
要点
- ATOMS装置在中位随访31个月后总体成功率为90%,干爽率为64%。
- 每日尿垫试验从400 mL降至18 mL,尿垫使用从4片降至1片(均P < 0.001)。
- 初次植入、良好身体健康和无放疗史是治疗获益的预后因素。
核心结论
- ATOMS装置安全,在迄今最大队列研究中显示出高治疗疗效和患者满意度。
- 最新一代带预 attached 硅胶覆盖阴囊端口的装置优于前代。
- 初次植入和无放疗史者获得显著更好的结果。
研究设计与样本
- 欧洲多中心研究,纳入287例2009年6月至2016年3月接受ATOMS装置治疗的压力性尿失禁男性。
- 比较术前与中期(12个月)及个体最大随访时的控尿参数、尿动力学、疼痛和生活质量评分。
- 记录总体成功率、干爽率(<10 mL/天且0-1片/天)、装置耐久性、治疗失败和装置并发症。
- 使用非参数检验进行统计分析。
主要发现
- 中位(IQR)随访31(10-54)个月,中位(IQR)调整3(2-4)次后,总体成功率为90%(258例),干爽率为64%(184例)。
- 每日尿垫试验从400 mL/天降至18 mL/天,尿垫使用从4片/天降至1片/天(均P < 0.001)。
- 生活质量评分显著改善:PGI-I从4降至2,ICIQ-SF从17降至5(均P < 0.001)。
- 12个月时的尿失禁结果与最终随访时相当。
- 无慢性疼痛和术中并发症发生;术后并发症多为Clavien-Dindo I-III级(无IV或V级)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term effectiveness and safety of the adjustable transobturator male system (ATOMS® , Agency for Medical Innovations A.M.I., Feldkirch, Austria) in a European-wide multicentre setting. PATIENTS AND METHODS: In all, 287 men with stress urinary incontinence (SUI) were treated with the ATOMS device between June 2009 and March 2016. Continence parameters (daily pad test/pad use), urodynamics (maximum urinary flow rate, voiding volume, residual urine), and pain/quality of life (QoL) ratings (visual analogue scale/Leeds Assessment of Neuropathic Symptoms and Signs, International Consultation on Incontinence Questionnaire-Short Form [ICIQ-SF]/Patient Global Impression of Improvement [PGI-I]) were compared preoperatively and after intermediate (12 months) as well as after individual maximum follow-up. Overall success rate, dry rate (<10 mL/day and 0-1 pad/day), device durability, treatment failure, and device complications were recorded. Nonparametric tests were used for statistical analyses. RESULTS: After a median (interquartile range [IQR]) follow-up of 31 (10-54) months and a median (IQR) of 3 (2-4) adjustments, the overall success rate was 90% (258 men) and the dry rate was 64% (184). Daily pad test and pad use decreased from a median of 400 mL/day and 4 pads/day to a median of 18 mL/day and 1 pad/day (both P < 0.001), concomitantly QoL ratings significantly improved and changed to a high level of satisfaction (PGI-I 4 to 2, ICIQ-SF 17 to 5; both P < 0.001). The UI results at 12 months were comparable to those at final follow-up. Chronic pain and intraoperative complications did not occur. Most of the postoperative complications were Clavien-Dindo grade I-III (no grade IV or V). At present, 231 (80%) of all the ATOMS devices are still functioning; 56 (20%) were removed, the most common reason being local titanium intolerance (41%) and leak/dysfunction (30%). The operating time and continence outcome varied between port generations. In this regard the latest port generation (silicone-covered scrotal port) was superior to its predecessors. Primary implantation (P = 0.002), good physical health (P = 0.001), and no history of radiotherapy (P < 0.001) were prognostic factors for beneficial treatment outcome. CONCLUSION: The ATOMS device is safe and shows high treatment efficacy and patient satisfaction in the largest cohort study to date. The latest generation, with its pre-attached silicone-covered scrotal port, is superior to its predecessors. Significantly better results were achieved with primary implantation and in those without a history of radiotherapy.
引用
- Friedl A, Mühlstädt S, Zachoval R, et al. Long-term outcome of the adjustable transobturator male system (ATOMS): results of a European multicentre study. BJU Int. 2016. PMID: 27868328. doi:10.1111/bju.13684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。